live
attenu
recombin
measl
virus
rmv
express
codonoptimis
spike
glycoprotein
nucleocapsid
protein
n
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
gener
rmv
rmvn
recombin
virus
stabli
express
correspond
sarscov
protein
grew
similar
end
titr
parent
strain
induc
high
antibodi
titr
mv
vector
sarscov
antigen
n
transgen
mice
suscept
measl
infect
antibodi
induc
rmv
high
neutralis
effect
sarscov
well
mv
moreov
signific
nspecif
cellular
immun
respons
measur
elispot
assay
preexist
antimv
antibodi
induc
initi
immunis
dose
inhibit
boost
anti
antin
antibodi
immunis
compris
mixtur
rmv
rmvn
induc
immun
respons
similar
magnitud
vaccin
compon
administ
separ
data
support
suitabl
mv
bival
candid
vaccin
vector
mv
emerg
virus
sarscov
outbreak
sever
acut
respiratori
syndrom
sar
contain
mean
tradit
health
care
measur
quarantin
coordin
scientif
activ
among
differ
academ
industri
laboratori
result
remark
progress
toward
understand
viru
associ
diseas
facilit
flow
vaccin
discoveri
effort
besid
standard
approach
use
inactiv
whole
viru
sarscov
vaccin
candid
nearli
known
deliveri
system
employ
develop
sar
candid
vaccin
sarscov
antigen
name
n
vector
dna
recombin
vaccinia
modifi
vaccinia
ankara
mva
adenoviru
rhabdovirus
parainfluenza
baculovirus
studi
employ
surfac
glycoprotein
antigen
neutralis
protect
immun
sarscov
shown
induc
sinc
safeti
sustain
immun
respons
toler
constitut
major
issu
vaccinolog
use
genet
modifi
vaccin
vector
exhibit
safe
histori
profil
undergon
substanti
develop
last
decad
among
vector
measl
viru
mv
vaccin
vector
mv
vector
base
live
attenu
mv
vaccin
document
safeti
efficaci
profil
mv
envelop
rna
viru
nonseg
genom
neg
polar
belong
famili
paramyxovirida
genu
morbilliviru
mv
vaccin
induc
longliv
immun
upon
one
two
lowdos
inject
inde
persist
antibodi
cell
shown
long
year
vaccin
sinc
attenu
mv
result
advantag
combin
numer
mutat
vaccin
stabl
revers
pathogen
never
observ
revers
genet
system
mv
establish
allow
rescu
infecti
mv
cdna
multipl
clone
site
introduc
mv
genom
allow
addit
multipl
foreign
gene
continu
express
progeni
viru
sever
marker
gene
gfp
lacz
gene
hepat
b
viru
hbv
simian
human
immunodefici
virus
siv
hiv
west
nile
viru
wnv
human
insert
mv
genom
correspond
virus
shown
express
gene
induc
humor
neutralis
antibodi
homolog
virus
mv
target
antigenpres
cell
gener
interact
repertoir
immun
system
properti
make
vector
attract
model
recombin
vaccin
develop
studi
investig
use
mv
vector
potenti
recombin
live
vaccin
sar
data
show
express
sarscov
n
rmv
induc
signific
neutralis
cellular
immun
respons
sarscov
vero
cell
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
calf
serum
fc
stabl
cell
line
maintain
dmem
supplement
fc
mg
per
ml
lysat
sarscov
urbani
strain
infect
vero
cell
prepar
center
diseas
control
prevent
cdc
atlanta
usa
rna
isol
use
trizol
ls
reagent
gibcobrl
life
technolog
first
strand
cdna
synthesis
use
cdna
cycl
kit
invitrogen
use
templat
subsequ
pcr
reaction
accuprim
pfx
invitrogen
expand
high
fidel
plu
pcr
system
roch
appli
scienc
dna
fragment
encod
sarscov
nucleocapsid
protein
n
amplifi
oligonucleotid
combin
forward
n
revers
n
pcr
fragment
clone
vector
use
topo
ta
clone
system
invitrogen
insert
result
plasmid
sarsn
sequenc
confirm
ident
microsynth
gmbh
balgach
switzerland
protein
express
test
vitro
transcriptiontransl
assay
addit
synthet
variant
spike
gene
optimis
human
codon
usag
clone
similarli
construct
synthesis
spike
gene
design
devoid
put
cisact
element
known
inhibit
mammalian
gene
express
amplif
gene
perform
pcr
use
oligonucleotid
forward
revers
fragment
subclon
use
topo
ta
clone
system
invitrogen
sar
gene
subclon
topo
plasmid
addit
transcript
unit
insert
mvp
mvm
code
sequenc
within
antigenom
measl
vector
p
mv
deriv
edmonston
zagreb
vaccin
strain
give
rise
p
mvsarscovn
p
mvsarscov
fig
insert
gene
segment
contain
nt
ngene
nt
sgene
subclon
step
perform
use
restrict
endonucleas
bsshii
aatii
boundari
region
newli
insert
express
site
confirm
sequenc
obtain
construct
correspond
rule
six
gener
correspond
recombin
virus
name
rmvn
rmv
initi
studi
sarscov
wild
type
sequenc
indic
protein
express
rel
low
therefor
experi
codonoptimis
gene
use
rescu
recombin
measl
virus
essenti
perform
describ
briefli
helper
cell
transfect
g
recombin
p
mv
deriv
maxiprep
qiagen
ng
pemcla
helper
plasmid
calcium
phosphat
transfect
invitrogen
format
syncytia
indic
success
rescu
event
monitor
microscopi
singl
syncytia
repres
individu
clone
recombin
mv
pick
store
c
use
stock
prepar
vero
cell
infect
multipl
infect
moi
pfucel
sarscov
spike
nucleocapsid
protein
detect
human
convalesc
antisar
serum
cdc
atlanta
usa
rabbit
antisar
n
antiserum
rabbit
antisar
spike
antiserum
purchas
imgenex
ca
usa
mous
antisarsassoci
coronaviru
mosaic
recombin
antigen
virogen
usa
use
elisa
western
blot
monoclon
antibodi
use
analys
ctermin
fusion
protein
express
drosophila
cell
invitrogen
fluoresc
isothiocyan
fitc
peroxidaseconjug
secondari
antibodi
purchas
sigma
dako
vero
cell
cultur
glass
coverslip
infect
either
parent
mv
recombin
mv
deriv
incub
period
h
cell
fix
paraformaldehyd
min
permeabilis
min
icecold
methanol
c
coverslip
incub
bsa
pb
min
block
unspecif
interact
human
convalesc
antisar
serum
use
dilut
pb
secondari
antihuman
fitclabel
antibodi
use
dilut
vero
cell
grown
confluenc
infect
recombin
mv
moi
pfucel
hpi
cell
scrape
wash
pb
lysi
perform
l
nonidet
mm
nacl
mm
tri
ph
presenc
cocktail
proteas
inhibitor
complet
mini
edta
free
roch
cell
debri
nuclei
pellet
rpm
min
supernat
prepar
sdspage
protein
separ
use
minigel
system
nupag
bistri
gel
invitrogen
transfer
immobilonp
membran
millipor
semidri
blot
unspecif
interact
block
mm
trishcl
ph
mm
nacl
tween
trisbuff
salin
tbstween
contain
skim
milk
room
temperatur
h
human
convalesc
antisar
serum
antisarscov
n
antibodi
dilut
tbstween
contain
skim
milk
incub
membran
room
temperatur
overnight
rabbit
antisar
n
antiserum
purchas
imgenex
ca
usa
use
dilut
rabbit
antisarsspik
antiserum
purchas
imgenex
usa
use
dilut
secondari
antihuman
peroxidaselabel
antibodi
use
dilut
peroxidas
activ
detect
use
chemoluminesc
substrat
supersign
west
pico
pierc
vero
cell
cultur
plate
infect
parent
recombin
mv
moi
pfucel
incub
c
cellfre
cellassoci
virus
collect
ml
optimem
daili
interv
cellular
debri
remov
centrifug
viru
titr
determin
plaqu
assay
ifnar
tm
mice
express
human
measl
receptor
humanlik
tissu
specif
addit
strain
defect
alphabeta
interferon
ifn
type
receptor
express
owe
inactiv
insert
alphabeta
interferon
allel
haplotyp
bk
ifnar
tm
transgen
mice
intraperiton
ip
immunis
pfu
cellfre
rmv
group
five
six
mice
gener
immunis
week
boost
indic
tabl
figur
legend
mice
bled
monthli
interv
serum
sampl
store
c
use
antimv
antibodi
titr
determin
accord
standard
protocol
briefli
plate
coat
gml
gml
solut
commerci
avail
mv
antigen
edmonston
atcc
virion
ltd
switzerland
sarscov
associ
antigen
virogen
usa
respect
plate
consecut
incub
variou
dilut
mous
sera
peroxidaseconjug
goat
antimous
igg
klp
opd
substrat
ophenylendiamin
fluka
optic
densiti
valu
measur
nm
valu
cutoff
background
level
mean
valu
sera
mvnaiv
mice
multipli
factor
consid
posit
titr
depict
reciproc
enddilut
mv
neutralis
antibodi
titr
determin
plaqu
reduct
neutralis
assay
incub
differ
serum
dilut
mv
titr
pfu
express
milliintern
unit
per
millilitr
miuml
accord
world
health
organis
standard
method
use
determin
presenc
neutralis
antibodi
sarscov
essenti
similar
previous
describ
briefli
serial
dilut
heatinactiv
serum
sampl
prepar
tissu
cultur
plate
total
volum
l
experi
perform
triplic
equal
volum
sarscov
viru
load
approxim
pfu
serumviru
mixtur
incub
cco
humidifi
incub
min
follow
addit
l
medium
mem
contain
vero
cell
well
virusload
backtitr
assay
perform
includ
posit
neg
control
plate
incub
cco
humidifi
incub
day
plate
stain
formaldehydecrystalviolet
stain
min
sar
titr
defin
reciproc
highest
dilut
serum
sampl
protect
least
triplic
well
complet
lysi
pcr
product
gener
use
templat
oligonucleotid
pair
forwardnkpni
reversenecori
digest
kpni
ecori
clone
correspond
site
drosophila
express
system
de
induc
kit
invitrogen
give
rise
schneider
cell
cultur
complet
schneider
drosophila
medium
c
stabl
cell
line
obtain
follow
instruct
manufactur
invitrogen
briefli
introduct
plasmid
dna
g
vector
contain
sar
gene
g
select
vector
pcoblast
cell
perform
calcium
phosphat
transfect
resist
cell
select
expand
medium
supplement
gml
nucleosid
antibiot
blasticidin
invitrogen
express
recombin
protein
exponenti
grow
cell
cellsml
induc
addit
cuso
final
concentr
h
protein
express
determin
cell
lysat
western
blot
analysi
use
either
human
convalesc
antisar
serum
monoclon
antibodi
total
protein
extract
wild
type
drosophila
cell
stabl
cell
express
protein
cell
per
lane
separ
sdspage
transfer
immobilonp
membran
membran
block
tbstween
contain
skim
milk
h
sera
mvn
immunis
mice
primeboost
well
anim
immunis
serv
control
unpublish
data
singl
pool
sera
mice
dilut
skim
milk
incub
h
room
temperatur
human
convalesc
antisar
serum
rabbit
antisar
n
monoclon
antibodi
appli
dilut
respect
peroxidaseconjug
secondari
antibodi
ad
incub
mixtur
h
room
temperatur
ninta
purif
system
invitrogen
isol
polyhistidinecontain
recombin
protein
use
purifi
recombin
protein
nativ
condit
stabl
cell
expand
total
cell
induc
day
harvest
wash
twice
pb
resuspend
recommend
buffer
solubl
protein
releas
cytoplasm
two
altern
freezethaw
cycl
use
liquid
nitrogen
c
water
bath
dna
shear
pass
lysat
four
time
needl
lysat
clear
centrifug
appli
ninta
resin
process
accord
instruct
result
fraction
test
presenc
recombin
protein
western
blot
analysi
use
antibodi
sarscov
nspecif
elisa
establish
measur
antibodi
sera
rmvn
immunis
transgen
mice
method
essenti
similar
standard
elisa
assay
except
sarscovn
protein
produc
inhous
use
coat
elisa
plate
sarscov
n
protein
recov
fusion
protein
epitop
sixtandem
histidin
tail
stabli
transfect
cell
see
use
intern
control
detect
specif
antibodi
histag
use
purifi
protein
nickel
column
ninta
chromatographi
fraction
consist
purifi
protein
stabl
cell
pool
use
coat
polystyren
plate
overnight
c
dilut
nucleocapsid
antigen
carbon
buffer
ph
l
per
well
purifi
protein
correspond
cellswel
wash
step
perform
autom
tecan
elisa
devic
tween
pbstween
block
perform
incub
skim
milk
pb
c
h
mous
sera
appli
start
dilut
consecut
incub
serial
dilut
pbstween
lwell
antibodi
dilut
pbstween
peroxidaselabel
secondari
goat
antimous
igg
antibodi
klp
dilut
pbstween
l
ad
well
detect
opd
tablet
ophenylendiamin
fluka
dissolv
ml
citrat
buffer
l
h
ad
l
per
well
distribut
reaction
stop
lwell
h
incub
time
min
absorb
nm
monitor
use
spectramax
micropl
spectrophotomet
molecular
devic
corp
od
valu
background
level
mean
od
valu
sera
naiv
mice
multipli
factor
reflect
clearli
posit
sampl
titr
depict
reciproc
enddilut
mous
elispot
assay
perform
follow
instruct
manufactur
ucytech
utrecht
netherland
briefli
splenocyt
cellswel
l
rpmi
medium
contain
fc
individu
mice
week
singl
immunis
pfu
ad
micropl
coat
antimous
antibodi
cell
subsequ
mix
either
equal
volum
medium
neg
control
medium
supplement
peptid
see
final
concentr
gml
ii
purifi
nucleocapsid
fusion
protein
l
pool
fraction
cell
express
iii
similar
extract
wild
type
cell
stimul
h
co
experi
preced
accord
instruct
manufactur
spot
monitor
count
dissect
microscop
use
bima
databas
bioinformat
molecular
analysi
section
http
bimascitnihgovmolbio
hla
bind
propredi
server
promiscu
mhc
classi
bind
peptid
predict
server
http
mhci
peptid
bind
predict
select
five
candid
peptid
order
assess
abil
rmvn
elicit
sarscovnspecif
tcell
respons
lsprwyfyyl
rwyfyylgt
ntaswftal
ltyhgaikl
gggetal
immunograd
qualiti
peptid
obtain
neomp
sa
strasbourg
franc
formerli
neosystem
sa
gene
encod
sarscov
nucleocapsid
protein
n
synthet
codonoptimis
spike
glycoprotein
gene
respect
insert
addit
transcript
unit
p
gene
recombin
antigenom
mv
plasmid
correspond
rmv
rescu
previous
report
standard
mv
recombin
virus
express
correspond
n
protein
demonstr
indirect
immunofluoresc
use
human
convalesc
antisar
serum
fig
detect
human
serum
shown
specif
sarscov
protein
cell
infect
standard
mv
show
background
reactiv
express
n
characteris
western
blot
analysi
lysat
rmv
rmvn
infect
vero
cell
probe
antiserum
protein
detect
rang
approxim
kda
kda
two
major
form
protein
differ
extent
glycosyl
base
nucleotid
sequenc
predict
full
length
unmodifi
protein
kda
potenti
glycosyl
site
n
protein
detect
rang
kda
expect
fig
extract
cell
infect
empti
mv
vector
react
serum
assess
result
differ
antisarscov
n
antibodi
employ
detect
protein
lysat
infect
cell
singl
mix
infect
recombin
perform
fig
show
differ
antibodi
specif
react
either
n
lysat
singl
recombin
viru
infect
rmv
rmvn
mix
infect
rmv
rmvn
similar
pattern
protein
observ
conclud
express
protein
sarsco
viru
especi
sinc
lysat
noninfect
empti
vectorinfect
cell
react
antibodi
insert
sarscov
gene
measl
genom
constitut
express
markedli
affect
viru
propag
growth
cell
cultur
compar
standard
mv
fig
paramet
necessari
maintain
especi
upscal
potenti
vaccin
need
immunogen
recombin
mv
evalu
transgen
mice
tgmice
ifnar
tm
suscept
mv
infect
although
tgmous
model
may
appear
optim
howev
uniqu
small
anim
model
effici
suscept
mv
infect
thu
use
screen
candid
mvbase
vector
move
forward
nonhuman
primat
group
five
mice
immunis
intraperiton
ip
pfu
either
viru
follow
homolog
boost
month
later
pool
serum
sampl
naiv
mice
mice
immunis
mv
rmv
rmvn
test
mv
sar
specif
antibodi
elisa
neutralis
assay
wherea
rmv
induc
high
titr
sarscov
neutralis
antibodi
virus
induc
compar
high
titr
antimv
igg
transgen
mice
tabl
interestingli
higher
neutralis
titr
induc
tgmice
inject
rmv
tabl
bracket
mean
immunis
mv
pfu
satur
immun
system
tgmice
also
observ
neutralis
titr
sarscov
mv
induc
rmv
immunis
mice
persist
period
month
termin
experi
taken
togeth
result
indic
rmv
effici
prime
boost
sarscovspecif
neutralis
antibodi
persist
till
termin
experi
sarscov
nspecif
antibodi
sera
rmvn
immunis
mice
measur
newli
develop
elisa
see
materi
method
monoclon
antibodi
use
intern
control
demonstr
presenc
fusion
protein
tabl
show
antin
igg
respons
rmvn
immunis
mice
period
week
pool
sera
collect
rmvn
vaccin
mice
contain
high
titr
nspecif
antibodi
wherea
antin
antibodi
detect
sera
naiv
mv
immunis
anim
interestingli
antin
igg
titr
decreas
slightli
time
reactiv
nspecif
antibodi
rmvn
immunis
mice
analys
immunoblot
analysi
extract
cell
express
protein
posit
control
monoclon
antibodi
commerci
polyclon
antin
sera
human
antisarscov
convalesc
serum
use
posit
control
specif
identifi
nucleocapsid
fusion
protein
approxim
kda
present
extract
stabli
transfect
cell
extract
wild
type
cell
fig
similarli
five
six
sera
rmvn
immunis
mice
collect
week
contain
antibodi
specif
react
protein
cross
reactiv
sera
protein
insect
cell
lysat
detect
although
serum
anim
posit
sensit
nspecif
elisa
assay
titr
appear
detect
limit
immunoblot
neg
control
pool
serum
mice
immunis
unrel
rmv
express
glycoprotein
hiv
unpublish
reveal
reactiv
sarscovn
humor
immun
respons
n
alon
might
relev
protect
vaccin
subject
sar
howev
experi
present
shed
import
inform
replic
rmv
presenc
antimv
antibodi
see
strong
antin
igg
respons
measur
month
rmvn
boost
clearli
demonstr
effici
viru
replic
n
expr
sion
prerequisit
induct
potent
cellular
immun
cellular
immun
respons
toward
n
may
play
role
cellmedi
cytotox
protect
capabl
splenocyt
immunis
mice
ifnar
tm
secret
evalu
elispot
assay
fig
fifteen
mice
three
group
five
mice
vaccin
singl
dose
rmvn
standard
mv
without
vaccin
naiv
splenocyt
stimul
purifi
express
cell
wild
type
extract
medium
averag
sarscov
nspecif
cell
per
splenocyt
rmvn
immunis
anim
count
upon
stimul
wherea
stimul
extract
result
low
background
activ
maximum
cell
fig
stimul
splenocyt
naiv
mv
immunis
anim
reveal
secret
cell
stimuli
omit
similar
basal
level
observ
sampl
order
assess
abil
rmvn
vaccin
elicit
nspecif
tcell
respons
five
candid
peptid
select
accord
bima
propredi
databas
predict
mhci
peptid
bind
see
materi
method
unfortun
none
peptid
induc
specif
secret
data
shown
like
peptid
optim
stimul
cell
transgen
mous
model
elisa
titr
end
serum
dilut
whose
od
valu
background
b
immunis
singl
inject
pfumous
uvinactiv
rmv
c
pool
preimmun
sera
anim
immunis
result
averag
mice
interest
whether
immunis
two
differ
recombin
mv
rmv
rmvn
simultan
induc
neutralis
igg
respons
toward
mv
vector
sarscov
similar
individu
antigen
administr
therefor
equal
dose
rmv
rmvn
half
previou
dose
ie
pfu
per
anim
mix
use
immunis
transgen
mice
tabl
show
sera
tgmice
immunis
mixtur
rmv
rmvn
contain
compar
titr
antimv
sarscovn
sarscov
immunis
either
recombin
rmv
rmvn
report
previous
immunis
tgmice
uvinactiv
mv
reduc
magnitud
antibodi
respons
viru
determin
whether
induct
antisarscov
antibodi
due
transgen
protein
contamin
viru
prepar
due
rmv
replic
tgmice
uvinactiv
virus
use
immunis
one
dose
pfu
uvinactiv
virus
appli
elisa
titr
measur
week
result
tabl
show
inactiv
rmv
fail
induc
antibodi
sarscov
elisa
replic
effici
viru
enabl
induct
antisarscov
antibodi
uvinactiv
mv
howev
induc
antimvantibodi
lower
titr
lower
titr
replic
viru
measur
igg
mv
mere
due
immunis
tgmice
viral
proteinoligom
inactiv
viru
therefor
induct
immun
respons
sarscov
rmv
requir
viru
replic
tgmice
mv
vaccin
previous
shown
elicit
antimv
immun
respons
context
preexist
antimv
immun
boost
humor
cellular
respons
use
recombin
mvsar
data
confirm
feasibl
boost
antimv
sarsspecif
immun
respons
presenc
antimv
immun
tabl
indic
mice
immunis
rmvn
induc
high
elisa
titr
toward
mv
sarscovn
readili
week
prime
upon
boost
rmvn
week
increas
antimv
antin
igg
measur
week
end
titr
antimv
antin
antibodi
increas
significantli
respect
maintain
high
level
week
could
argu
virus
standard
mv
rmvn
boost
antimv
respons
without
need
viru
replic
essenti
mvprotein
compon
viru
howev
sinc
sarscovn
structur
part
virion
boost
antin
antibodi
level
requir
rmvn
infect
cell
express
addit
transgen
sarscovn
gene
encod
viral
genom
fact
failur
uvinactiv
rmv
induc
antibodi
sarscov
strongli
suggest
rmv
replic
tgmice
integr
induct
antibodi
vector
antigen
tabl
therefor
consider
increas
antin
antibodi
boost
rmvn
due
viru
replic
presenc
preexist
antimv
antibodi
similarli
week
postimmunis
mice
boost
rmv
express
sarscov
increas
sarscov
neutralis
titr
also
observ
tabl
boost
antisarscov
antibodi
occur
presenc
antimv
antibodi
data
demonstr
preexist
mv
neutralis
antibodi
inhibit
effici
replic
rmv
sever
affect
induct
strong
immun
respons
toward
foreign
protein
express
rmv
quest
sar
vaccin
manifest
intens
outbreak
past
year
sever
strategi
sar
suggest
vaccin
sar
includ
inactiv
sarscov
viral
vector
adenoviru
vaccinia
rhabdoviru
recombin
sarscov
protein
dnabas
vaccin
review
see
et
al
surfac
glycoprotein
employ
primari
target
prophylact
vaccin
candid
induc
viru
neutralis
antibodi
report
also
show
live
attenu
recombin
mv
vaccin
induc
high
level
neutralis
antisarscov
antibodi
addit
recombin
mv
express
sarscovn
antigen
induc
humor
cellular
immun
respons
n
protein
although
addit
sarscov
gene
increas
mv
genom
effici
replic
abil
induc
neutralis
antimv
antibodi
affect
interestingli
immun
respons
toward
mv
vector
sarsantigen
persist
week
termin
experi
suggest
suitabl
rmv
vaccin
vector
sar
claim
vaccin
sarscov
howev
result
obtain
mileston
toward
develop
futur
sinc
mv
tropism
limit
nonhuman
primat
pose
ethic
hurdl
perform
challeng
studi
howev
quantit
comparison
magnitud
neutralis
titr
obtain
studi
togeth
previou
studi
suggest
highli
persist
titr
neutralis
antisar
antibodi
might
also
protect
sever
studi
corona
viru
vaccin
research
highlight
experi
felin
infecti
periton
corona
viru
vaccin
report
enhanc
diseas
rather
protect
immunis
subject
moreov
studi
use
recombin
mva
express
protein
sarscov
show
enhanc
hepat
challeng
ferret
despit
induct
neutralis
antibodi
although
effect
observ
applic
vector
review
known
whether
ferret
model
faith
reflect
symptom
patholog
human
diseas
agreement
earlier
report
identifi
protein
major
antigen
develop
sar
vaccin
cell
deplet
passiv
transfer
antibodi
indic
humor
immun
respons
antigen
appear
suffici
protect
cellular
immun
respons
appear
play
limit
role
protect
howev
studi
anim
corona
virus
suggest
cellular
humor
immun
may
contribut
protect
sinc
sarscov
infect
spread
system
confin
respiratori
tract
induct
cellular
immun
may
constitut
anoth
boundari
viru
infect
spread
inde
kim
et
al
observ
signific
reduct
challeng
viru
upon
vaccin
recombin
dna
express
sarsn
line
hypothesi
ctl
activ
sarscovn
may
import
protect
express
n
rmv
elicit
quantit
cellular
immun
respons
measur
elispot
assay
compar
previou
report
induct
cellular
immun
rmv
therefor
qualit
signific
gener
believ
effect
mean
protect
vaccin
activ
arm
immun
system
context
vaccin
combin
sarscov
antigen
induc
neutralis
cellular
immun
n
may
constitut
ideal
approach
consid
perform
experi
combin
two
rmv
rmv
rmvn
one
immunis
dose
demonstr
induct
humor
neutralis
cellular
respons
sarscov
neutralis
immun
mv
neutralis
cellular
immun
induc
singl
immunis
dose
prove
suitabl
rmv
multival
vaccin
approach
develop
recombin
mv
base
mv
vaccin
strain
good
record
safeti
efficaci
parenter
mucos
vaccin
unlik
rna
virus
mv
genom
stabl
recombin
vector
stabli
express
heterolog
gene
make
mv
ideal
vaccin
vector
argu
presenc
antimv
antibodi
major
adult
popul
might
restrict
applic
mv
recombin
infant
rather
adult
howev
sever
studi
result
report
suggest
recombin
mv
vaccin
could
administ
preimmunis
human
follow
reason
revaccin
alreadi
immunis
school
children
measl
vaccin
aerosol
parenter
vaccin
shown
result
boost
antimv
respons
addit
presenc
matern
antibodi
shown
limit
induct
antimeasl
antibodi
infant
first
year
life
howev
inhibit
specif
tcell
respons
ii
vaccin
preimmunis
mice
primat
recombin
mvhiv
shown
induct
antihivenv
antibodi
presenc
antimv
antibodi
iii
final
studi
observ
signific
boost
anti
antin
antibodi
mice
preimmunis
rmv
rmvn
result
present
previou
studi
open
possibl
use
live
attenu
mvderiv
vector
immunis
adult
optim
preexist
antibodi
titr
allow
effici
immunis
mv
vector
howev
need
determin
detail
primat
model
lay
ground
futur
clinic
studi
pursu
technolog
sar
also
diseas
consid
promis
mv
vaccin
safe
even
hiv
patient
highli
immunogen
among
afford
vaccin
use
mass
immunis
campaign
worldwid
